Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Trial Profile

Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs MVT 1075 (Primary) ; MVT 5873
  • Indications Colon cancer; Lung cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 13 Dec 2017 According to a MabVax Therapeutics media release, interim results from this study are expected in the first quarter of 2018.
    • 13 Dec 2017 According to a MabVax Therapeutics media release, enrollment and dosing of all patients in the initial cohort has been completed.
    • 17 Oct 2017 According to a MabVax Therapeutics media release, the company anticipates to report interim data from the study near the end of the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top